{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:20:57Z","timestamp":1789158057980,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Municipal Hospital Scientific Research and Cultivation Program","award":["PX2022024"],"award-info":[{"award-number":["PX2022024"]}]},{"name":"Beijing Hospital Authority Young Talent Cultivation \u201cQingmiao\u201d Program","award":["QML20230601"],"award-info":[{"award-number":["QML20230601"]}]},{"name":"Special Project for Scientific Research on Health Development of the Capital","award":["2022-2-2066"],"award-info":[{"award-number":["2022-2-2066"]}]},{"name":"Beijing Municipal Hospital Scientific Research and Cultivation Program","award":["PX2022024"],"award-info":[{"award-number":["PX2022024"]}]},{"name":"Beijing Hospital Authority Young Talent Cultivation \u201cQingmiao\u201d Program","award":["QML20230601"],"award-info":[{"award-number":["QML20230601"]}]},{"name":"Special Project for Scientific Research on Health Development of the Capital","award":["2022-2-2066"],"award-info":[{"award-number":["2022-2-2066"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Higher serum phospholipase A2 receptor antibody is an independent risk factor of arterial and venous thromboembolic events in patients with primary membranous nephropathy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The inflammatory system may play a role in this relationship.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study investigated risk factors and possible mechanisms of arterial and venous thromboembolic events in patients with primary membranous nephropathy (pMN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with pMN confirmed by renal biopsy from June 1, 2010, to March 3, 2023, were included, and the study outcome was set as a composite end point of acute coronary syndrome, heart failure, cerebral infarction, arrhythmia, pulmonary embolism, deep venous thrombosis, and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 433 pMN patients with complete data were included, with a median follow-up time of 73 (45.5\u2013101.6) months and a composite end point rate of 10.2%. We divided all patients with events into an early event group (events occurring in the first 2 years after renal biopsy) and a late event group (events occurring after 2 years after renal biopsy) according to the time of event. It showed a lower serum albumin and higher baseline value of serum phospholipase A2 receptor (PLA2R) antibody titer and mean value of each follow-up in the early event group compared with the late event group. Cox proportional hazards model showed that after adjusting for confounding factors, in addition to older age, history of deep vein thrombosis and higher urinary protein, higher baseline serum PLA2R antibody titers (odds ratio [OR], 1.034; 95% confidence interval [CI], 1.006 to 1.063;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015), and high high-sensitivity C-reactive protein level (OR, 1.049; 95% CI, 1.002 to 1.098;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041), renal pathology with segmental sclerotic lesions (OR, 3.480; 95% CI, 1.338 to 9.050;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011) were also independent risk factors for the occurrence of end point events. The results also showed that baseline serum IL-6 levels were significantly higher in the event group compared with the nonevent group (4.25 versus 3.21 pg\/ml), and the difference was statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the early event group, higher serum PLA2R antibody and renal pathology with segmental sclerosis lesions may affect the occurrence of cardiovascular, cerebrovascular, and venous thrombotic events. The inflammatory system may play a role in this relationship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000000739","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:21:39Z","timestamp":1740140499000},"page":"997-1006","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Cardiovascular and Cerebrovascular Prognosis and Risk Factors in Patients with Primary Membranous Nephropathy"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9339-9361","authenticated-orcid":false,"given":"Nan","family":"Ye","sequence":"first","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-6830","authenticated-orcid":false,"given":"Guoqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-9315","authenticated-orcid":false,"given":"Wenrong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xie","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Dong","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqiang","family":"Kong","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Renal Division, Affiliated Hospital of Chifeng University, Neimenggu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Geng","sequence":"additional","affiliation":[{"name":"Renal Division, Third Medical Center, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-3333","authenticated-orcid":false,"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"7654","key":"B1-20250626","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ."},{"issue":"2","key":"B2-20250626","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int."},{"issue":"1","key":"B3-20250626","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B4-20250626","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2215\/CJN.11791111","article-title":"Venous thromboembolism and membranous nephropathy","volume":"7","author":"Radhakrishnan","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"38","key":"B5-20250626","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J."},{"issue":"3","key":"B6-20250626","first-page":"235","article-title":"Chinese guidelines for the diagnosis and treatment of heart failure 2024","volume":"52","year":"2024","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi."},{"issue":"5","key":"B7-20250626","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","article-title":"Patients with primary membranous nephropathy are at high risk of cardiovascular events","volume":"89","author":"Lee","year":"2016","journal-title":"Kidney Int."},{"issue":"2","key":"B8-20250626","doi-asserted-by":"crossref","first-page":"91","DOI":"10.24920\/11809","article-title":"A cohort study of incidences and risk factors for thromboembolic events in patients with idiopathic membranous nephropathy","volume":"33","author":"Zou","year":"2018","journal-title":"Chin Med Sci J."},{"issue":"7","key":"B9-20250626","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/imj.14146","article-title":"Acute arterial cardiovascular events risk in patients with primary membranous nephropathy","volume":"49","author":"Alawami","year":"2019","journal-title":"Intern Med J."},{"issue":"6","key":"B10-20250626","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.ajkd.2022.04.005","article-title":"The risk of cardiovascular events in individuals with primary glomerular diseases","volume":"80","author":"Canney","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"B11-20250626","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1681\/ASN.2020111583","article-title":"Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: the kaiser permanente nephrotic syndrome study","volume":"32","author":"Go","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B12-20250626","doi-asserted-by":"crossref","first-page":"e23988","DOI":"10.1097\/MD.0000000000023988","article-title":"Clinicopathologic characteristic and prognosis in idiopathic membranous nephropathy patients with focal segmental sclerosis lesion: a retrospective observational study","volume":"100","author":"Cheng","year":"2021","journal-title":"Medicine."},{"issue":"6","key":"B13-20250626","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B14-20250626","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol."},{"issue":"11","key":"B15-20250626","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res."},{"issue":"8","key":"B16-20250626","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/CIRCRESAHA.122.321749","article-title":"Innate immunity system in patients with cardiovascular and kidney disease","volume":"132","author":"Zoccali","year":"2023","journal-title":"Circ Res."},{"issue":"7","key":"B17-20250626","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4155\/fmc-2019-0301","article-title":"A perspective on targeting inflammation and cytokine actions in atherosclerosis","volume":"12","author":"Chan","year":"2020","journal-title":"Future Med Chem."},{"issue":"8","key":"B18-20250626","doi-asserted-by":"crossref","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harbor Perspect Biol."},{"issue":"6057","key":"B19-20250626","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.1208421","article-title":"Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection","volume":"334","author":"Harker","year":"2011","journal-title":"Science."},{"issue":"5","key":"B20-20250626","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6\u2013producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J Exp Med."},{"issue":"11","key":"B21-20250626","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/nm.3680","article-title":"Regulatory B cells are induced by gut microbiota-driven interleukin-1\u03b2 and interleukin-6 production","volume":"20","author":"Rosser","year":"2014","journal-title":"Nat Med."},{"issue":"10289","key":"B22-20250626","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet."},{"issue":"1","key":"B23-20250626","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"issue":"11","key":"B24-20250626","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.mayocp.2023.08.006","article-title":"Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"98","author":"Sethi","year":"2023","journal-title":"Mayo Clinic Proc."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:59:36Z","timestamp":1786478376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000739","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"2024-11-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}